glp 1 medullary thyroid cancer GLP-1 Receptor Agonists and Risk, Rodent Data and FDA Warning, • In rodents, GLP-1 receptor agonists (GLP-1 RAs) stimulate thyroid C-cells, increasing the incidence of thyroid No Increased Risk for Thyroid

Preliminary research suggests that people whove used GLP-1 drugs to reach a healthy weight can spread out their injections without regaining lost pounds.

Featuring Akkermansia, known for promoting metabolic balance and supporting weight management efforts

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

These medicines work best when used as ongoing treatment, similar to medicine for high blood pressure or diabetes

In the case of Viking Therapeutics (VKTX), I believe the exercise is worth the effort given the rapid adoption of GLP-1 agonists (sometimes referred to as incretins), for the treatment of diabetes and weight loss -